Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab.
Sutton R, Pozza LD, Khaw SL, Fraser C, Revesz T, Chamberlain J, Mitchell R, Trahair TN, Bateman CM, Venn NC, Law T, Ong E, Heatley SL, McClure BJ, Meyer C, Marschalek R, Henderson MJ, Cross S, White DL, Kotecha RS. Sutton R, et al. Among authors: venn nc. Pediatr Blood Cancer. 2021 May;68(5):e28922. doi: 10.1002/pbc.28922. Epub 2021 Feb 26. Pediatr Blood Cancer. 2021. PMID: 33638292
Two cases of hypereosinophilia and high-risk acute lymphoblastic leukemia.
Sutton R, Lonergan M, Tapp H, Venn NC, Haber M, Norris MD, O'Brien TA, Alvaro F, Revesz T. Sutton R, et al. Among authors: venn nc. Leukemia. 2008 Jul;22(7):1463-5. doi: 10.1038/sj.leu.2405096. Epub 2008 Jan 17. Leukemia. 2008. PMID: 18200036 No abstract available.
Mechanism of relapse in pediatric acute lymphoblastic leukemia.
Henderson MJ, Choi S, Beesley AH, Sutton R, Venn NC, Marshall GM, Kees UR, Haber M, Norris MD. Henderson MJ, et al. Among authors: venn nc. Cell Cycle. 2008 May 15;7(10):1315-20. doi: 10.4161/cc.7.10.5885. Epub 2008 Feb 29. Cell Cycle. 2008. PMID: 18418081 Free article.
Sensitive and specific measurement of minimal residual disease in acute lymphoblastic leukemia.
Morley AA, Latham S, Brisco MJ, Sykes PJ, Sutton R, Hughes E, Wilczek V, Budgen B, van Zanten K, Kuss BJ, Venn NC, Norris MD, Crock C, Storey C, Revesz T, Waters K. Morley AA, et al. Among authors: venn nc. J Mol Diagn. 2009 May;11(3):201-10. doi: 10.2353/jmoldx.2009.080048. Epub 2009 Mar 26. J Mol Diagn. 2009. PMID: 19324989 Free PMC article.
Determining the repertoire of IGH gene rearrangements to develop molecular markers for minimal residual disease in B-lineage acute lymphoblastic leukemia.
Brisco MJ, Latham S, Sutton R, Hughes E, Wilczek V, van Zanten K, Budgen B, Bahar AY, Malec M, Sykes PJ, Kuss BJ, Waters K, Venn NC, Giles JE, Haber M, Norris MD, Marshall GM, Morley AA. Brisco MJ, et al. Among authors: venn nc. J Mol Diagn. 2009 May;11(3):194-200. doi: 10.2353/jmoldx.2009.080047. Epub 2009 Mar 26. J Mol Diagn. 2009. PMID: 19324994 Free PMC article.
Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD; Australian and New Zealand Children's Oncology Group. Sutton R, et al. Among authors: venn nc. Br J Haematol. 2009 Aug;146(3):292-9. doi: 10.1111/j.1365-2141.2009.07744.x. Epub 2009 Jun 3. Br J Haematol. 2009. PMID: 19500099 Free article. Clinical Trial.
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R. Marshall GM, et al. Among authors: venn nc. Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14. Leukemia. 2013. PMID: 23407458 Clinical Trial.
46 results